The sensitivity of antibody detection testing using pooled versus unpooled reagent red cells by Shulman, Ira A. et al.
The sensitivity of antibody 
detection testing using pooled 
versus unpooled reagent red cells 
I.A. SHULMAN, R. NAKAYAMA, AND C. CALDERON 
Because the sensitivity of antibody detection testing may be reduced 
when pooled reagent red blood cells (RBCs) are used, the American 
Association of Blood Banks (AABB) prohibits the use of pooled 
reagent RBCs when performing pretransfusion antibody detection 
testing. This restriction imposed upon the use of pooled reagent 
RBCs is based, at least in part, on the belief that pooled reagent 
RBCs are less likely to detect clinically significant antibodies than 
are sets of unpooled reagent RBCs. Little data, however, have been 
published to support this contention. In the present study, the data 
show a decreased sensitivity for antibody detection when pooled 
reagent RBCs are used. This reduced sensitivity could result in failure 
to detect some clinically significant RBC alloantibodies, which might 
result in the occurrence of overt hemolytic transfusion reactions, 
especially if an indirect antiglobulin test is not performed at the 
time blood is crossmatched. Immunohematology 1991;1:16-19 
Occurrences of acute and delayed hemolytic transfu- 
sion reactions are decreased when unexpected red cell 
antibodies are detected prior to blood transfusion. sup(1) 
According to the Food and Drug Administration (FDA), 
18 specific red cell antigens must be present on com- 
mercial reagent red blood cells (RBCs) that are used for 
antibody detection testing. These antigens are D, C, E, 
c, e, K, k, Fysup(a), Fysup(b), Jksup(a), Jksup(b), Lesup(a), Lesup(b), Psub(1), M, N, S, and 
s.sup(2) Since it is virtually impossible to find an adult whose 
RBCs express all 18 FDA-required antigens, group O 
RBCs suitable by FDA regulation for antibody screen- 
ing are offered commercially either as a set of two or 
three vials, each containing RBCs from a single donor, 
or as a single vial containing a pool of equal volumes 
of RBCs from two donors (“pooled reagent RBCs”). 
Because the sensitivity of antibody detection testing 
may be reduced when pooled reagent RBCs are used,sup(3) 
the American Association of Blood Banks (AABB) 
prohibits the use of pooled reagent RBCs when 
performing pretransfusion antibody detection testing.sup(4) 
However, the AABB does allow pooled reagent RBCs 
to be used when testing donor blood samples for unex- 
pected red cell antibodies.sup(4,5) 
Unlike the AABB, the College of American 
Pathologists (CAP) does not mandate the use of unpooled 
reagent RBCs for antibody detection testing? nor does 
the FDA,’ although the FDA requires the package label 
or insert of “pooled reagent RBCs” to indicate that this 
reagent is not recommended for pretransfusion antibody 
detection testing if antibody detection tests are done 
in lieu of a major crossmatch 7 
The restrictions imposed on the use of pooled reagent 
RBCs are based, at least in part, on the belief that pooled 
reagent RBCs are less likely to detect clinically significant 
antibodies than are sets of unpooled reagent RBCs. Little 
data, however, have been published to support this con- 
tention. In a study done at the authors’ institution, only 
90.3 percent of sera known to contain antibodies with 
Kidd, Kell, Duffy, and/or Rhesus blood group system 
specificities agglutinated pooled reagent RBCs in one 
or more phases of testing, whereas 100 percent of these 
same sera agglutinated one or both cells in each set of 
unpooled reagent RBCs.sup(3) The pooled RBCs used in that 
study were not commercially prepared, and antibody 
detection testing was done using two drops of a pa- 
tient’s serum, two drops of 22 percent albumin, a 
20-minute 37°C incubation step, and an indirect an- 
tiglobulin test @‘ using an IgG reagent. Currently, the 
authors’ laboratory performs antibody detection testing 
using three drops of serum, no albumin or LISS, a 
30-minute 37°C incubation step, and IgG antihuman 
globulin reagent. The present study was designed to 
compare the sensitivity of commercially prepared 
pooled versus unpooled reagent RBCs to detect clinically 
significant RBC antibodies 
Materials and Methods 
Initial detection of unexpected red cell antibodies 
All antibody screening tests and the grading of 
agglutination reactions were done using standard tech- 
niques.sup(5) Freshly drawn serum samples of potential 
transfusion recipients were screened for unexpected 
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RBC antibodies using a two-vial set of commercially 
prepared reagent RBCs (manufacturers included Gamma 
Biologicals, Houston, TX; Organon Teknika Corp., 
Malvern, PA; Immucor Inc., Norcross, GA; and Baxter 
Healthcare Corp., Deerfield, IL). One vial in each set 
always contained Rsup(1)Rsup(1) red cells and the other, Rsub(2)Rsub(2) 
red cells. In addition, one of the two cells in each set 
was always Jk(a+b-). AU other RBC antigen specificities 
added to one drop of reagent RBCs, followed by an 
immediate spin reading, a reading after a 37°C, 
30-minute incubation, and an IgG IAT after washing 
the RBCs three times with 0.9 percent NaCI. IgG-coated 
red cells (antiglobulin control) were used when negative 
reactions were obtained in the antihuman globulin phase 
of testing. 
Comparison of antibody detection test sensitivities 
Serum samples containing clinically significant red 
cell alloantibodies were assigned study case numbers 
and stored at 4°C. Samples were retested within 24 
hours of collection with the same lot of unpooled 
reagent RBCs that initially detected the unexpected 
antibody, as well as with commercially prepared pooled 
reagent RBCs (Hemantigen, Immucor). The pooled 
reagent RBCs varied in antigen zygosity from lot to lot, 
but each lot met FDA requirements for antigen expres- 
sion on RBCs.sup(2) 
In order to avoid bias when comparing the antibody 
detection test sensitivity, serum samples were identified 
only with their case numbers (the antibody specificities 
were not known by the technologist performing the 
comparison testing). Reagent RBCs (pooled and un- 
pooled) were randomly distributed among three coded 
met FDA requirements.sup(2) Three drops of serum were 
test tubes so that the technologist performing the com- 
parison testing would also be blinded as to what reagent 
RBC corresponded to which tube. Test results were not 
matched with either the serum sample case numbers 
or the reagent RBC antigenic phenotypes until after 
testing was completed. 
Comparison testing was performed by adding three 
drops of serum to one drop of RBCs (pooled reagent 
RBCs, Rsup(1)Rsup(1) RBCs, or Rsup(2)Rsup(2) RBCs, as described above). 
The serum-cell mixture was immediately centrifuged 
and examined for hemolysis and agglutination. This 
step was followed by a 37°C, 30-minute incubation, 
centrifugation, and reading; and then by an IAT using 
an IgG reagent. IgG-coated red cells (antiglobulin control) 
were used when negative reactions were obtained in 
the IgG IAT. 
Results 
One hundred different serum samples containing 
antibodies with Kidd, Kell, Duffy, and/or Rhesus blood 
group specificities (Table 1) were tested with pooled 
and unpooled reagent RBCs. 
When unpooled reagent RBCs were used, 99 of 100 
serum samples (Table 1) showed macroscopic agglutina- 
tion in the IAT phase of testing. The one serum sam- 
ple that did not show agglutination in the IAT showed 
w +  agglutination at the 37°C reading and contained 
anti-E. (Table 2) 
When pooled reagent RBCs were used, 93 of the 100 
serum samples (Table 1) showed macroscopic agglutina- 
tion in the IAT phase of testing. Of the seven serum 
samples that did not show a macroscopic reaction, two 
(Table 2) did not show agglutination or hemolysis in 
any phase of testing. One of these “nonreactive” samples 
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contained anti-K, and the other contained anti-c plus 
anti-E. The remaining five serum samples (Table 2) 
showed agglutination at the 37°C reading. These five 
serum samples contained anti-E. 
Table 2 .  Serum samples containing antibodies that failed to 
agglutinate pooled and/or unpooied reagent red blood cells (RBCs) 
at the indirect antiglobulin test (IAT) 
Antibody Strength of agglutination Strength of agglutination 
specificity with pooled reagent RBCs with unpooled reagent RBCs 
at 37°C 
anti-K 0 
anti-c + E 0 
anti-E w +  
anti-E w +  
anti-E 1+ 
anti-E w+ 
anti-E w + 
at the IAT at 37°C at the IAT 
0 0 w +  
0 w+ w +  
0 1+ w +  
0 2 +  w+ 
0 I t  w +  
0 1 +  w +  
0 w +  0 
The strength of agglutination in the IAT seemed to 
be stronger when unpooled reagent RBCs were used. 
Forty-six of the serum samples showed stronger 
agglutination reactions in the IAT when they were tested 
with unpooled reagent RBCs, and 51 samples showed 
similar strength agglutination with both pooled and 
unpooled reagent RBCs. Three samples showed stronger 
agglutination reactions with pooled RBCs. 
Discussion 
In a previous study done at the authors’ institution, 
only 90.3 percent of sera known to contain antibodies 
with Kidd, Kell, Duffy, and/or Rhesus blood group 
system specificities agglutinated pooled reagent RBCs 
in one or more phases of testing, whereas 100 percent 
of these sera agglutinated one or both cells in each set 
of unpooled reagent RBCs.sup(3) 
In the present study, when pooled reagent RBCs were 
used, 2 percent of the serum samples containing poten- 
tially significant RBC alloantibodies (anti-K and anti- 
c plus anti-E) failed to cause macroscopic reactions in 
any phase of testing, and an additional 5 percent failed 
to react at the IAT. In contrast, when unpooled reagent 
RBCs were used, 100 percent of serum samples tested 
caused macroscopic agglutination of unpooled reagent 
RBCs in at least one phase of testing, and 99 percent 
showed agglutination in the IAT. In addition, the serum 
samples tested tended to show stronger agglutination 
reactions with unpooled reagent RBCs (46% of the time) 
than with pooled reagent RBCs (3% of the time). 
It is interesting that 1 percent of the serum samples 
agglutinated unpooled and 5 percent agglutinated pooled 
reagent RBCs at 37°C but not at the IAT; in all cases 
these serum samples contained anti-E. These data suggest 
that some clinically significant antibodies might be 
missed by antibody screening if only an IAT reading 
is done, especially if pooled reagent RBCs are used for 
antibody detection. Because the antibody detection 
testing in this study was done without the use of a 
potentiating medium (such as albumin or LISS), we can- 
not generalize this observation to laboratories that use 
potentiating media with antibody detection testing. 
However, certain antibody detection techniques, such 
as “prewarmed’ testing, do not use potentiating media 
and are read only for agglutination at the IAT.sup(5) Thus, 
prewarmed testing might miss some potentially signifi- 
cant antibodies. 
The AABB prohibits the use of pooled reagent RBCs 
for routine pretransfusion testing of prospective transfu- 
sion recipients.sup(4) This restriction seems justified in light 
of the data published previouslysup(3) and the dan observed 
in this study. The use of pooled reagent RBCs decreases 
the sensitivity of antibody detection, possibly because 
pooled RBCs do not present an optimum ratio of anti- 
gen to antibody. This reduced sensitivity could result 
in the failure to detect some clinically significant RBC 
alloantibodies, which might result in the occurrence 
of overt hemolytic transfusion reactions, especially if 
an IAT is not performed at the time blood is 
crossmatched.sup(8) 
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A N N O U N C E M E N T S  
American Association of Blood Banks and Ameri- 
can Red Cross Fourth Joint Immunohematology 
Reference Laboratory Conference. The Reference 
Rare Patient Needs 
Transfusion Naomi L.C. Luban, MD 
Alternatives Washington, DC 
Rare Frozen Blood 
Untested for Infectious Nashville, TN 
Disease Markers– 
Should It Be 
Transfused? 
Compatibility Malcolm L. Beck, FIMLS 
Testing-Current Kansas City, MO 
Concepts 
Edwin A. Steane, PhD 
Case Study Session 
The Worst Case 
I Ever Worked On.  . . 
Joyce Poole, FIMLS 
Bristol, England, and 
Malcolm L. Beck, FIMLS 
Kansas City, MO 
Case Studies Small Group Discussion 
laboratory Conference will be held on March 22-24, 
1991, at the Dulles Marriott in Herndon, Virginia. The 
program includes the subjects listed below. 
Blood Group Review 
Blood Group 
Antigens on Phos- Durham, NC 
phatidylinositol- 
Linked RBC Mem- 
brane Proteins 
The Lutheran Blood 
Group System-1991 Bristol, England 
Transfusion-Associated P. Ann Hoppe 
Fatalities--Past, Bethesda, MD 
Present, and Future 
There will be poster presentations, a fun run, and an 
evening of blood bank games. Contact: Call Meeting 
Registrar at (703) 247-0520. 
Marilyn J. Telen, MD 
Joyce Poole, FIMLS 
Announcements continued on p.  24. 
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